Pyridine

Pyridine

SCHEMBL6794850

CCOC(=O)c1cc2c(C)c(OS(=O)(=O)[O-])ccc2n1C.[H+].c1ccncc1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 3/20 0.37
LMNA P02545 2/20 0.37
GAA P10253 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
ELANE P08246 3/20 0.36
KMT2A Q03164 2/20 0.36
NOD2 Q9HC29 3/20 0.35
NOD1 Q9Y239 3/20 0.35
MAPT P10636 1/20 0.35
MEN1 O00255 1/20 0.35
ALOX5 P09917 1/20 0.35
MAOA P21397 1/20 0.35
SCARB1 Q8WTV0 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL6794846 0.90 ALDH1A1 (0.39) TSHRNPSR1ALDH1A1KDM4ELMNA
SCHEMBL7246268 0.81 ALDH1A1 (0.41) TSHRALDH1A1KDM4ELMNAGAA
SCHEMBL6797552 0.74 KDM4E (0.49) ALDH1A1KDM4ELMNAGAASMN1; SMN2
SCHEMBL6793058 0.71 MAPT (0.34) ALDH1A1KDM4ELMNAGAAHPGD
SCHEMBL6798709 0.71 ALDH1A1 (0.46) ALDH1A1KDM4ELMNAGAASMN1; SMN2
Hydrochloric Acid SCHEMBL13684574 0.69 MAPT (0.52) TSHRALDH1A1KDM4ELMNAGAA
SCHEMBL3059209 0.67 MAPT (0.51) ALDH1A1KDM4ELMNASMN1; SMN2ELANE
SCHEMBL7882131 0.67 KDM4E (0.47) TSHRALDH1A1KDM4ELMNAGAA
SCHEMBL7881078 0.67 KMT2A (0.50) TSHRALDH1A1KDM4ELMNAGAA
SCHEMBL7873678 0.67 KDM4E (0.46) TSHRALDH1A1KDM4ELMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734205-B2 SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2004-05-11 US disclosed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US disclosed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 TSHR 1959/4885NPSR1 2593/4885ALDH1A1 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.